Palazestrant is under clinical development by Olema Pharmaceuticals and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase III drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Palazestrant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Palazestrant overview

Palazestrant (OP-1250) is under development for the treatment of metastatic HR positive and HER2 negative breast cancer, endometrial cancer, ER positive and HER2 positive breast cancer and gynaecological malignancies. It is administered by oral route in the form of tablet or pill. The drug candidate is a selective estrogen receptor degrader (SERD) and acts by targeting estrogen receptor (ESR).

Olema Pharmaceuticals overview

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company that discovery, development, and commercialization of next-generation targeted therapies for women’s cancers. The company’s lead product candidate is palazestrant (OP-1250), a novel, orally-available small molecule with dual activity as both a complete estrogen receptor antagonist and selective estrogen receptor degraded. Olema Pharmaceuticals operates in multiple locations, including San Francisco, California, and Cambridge, Massachusetts, the US. Olema Oncology is headquartered in San Francisco, California, United States.

For a complete picture of Palazestrant’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.